The expression of CXCR3 and CD30 in mycosis fungoides

Archives of Iranian Medicine

Volumn 15, Issue 3, 2012, Pages 146-150

  Nikoo, Azita ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CD30; Cytokines; Mycosis fungoides

Indexed keywords

CD30 ANTIGEN; CHEMOKINE RECEPTOR CXCR3;

ANTIGEN EXPRESSION; ARTICLE; CD30+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYCOSIS FUNGOIDES; PROTEIN EXPRESSION; SKIN BIOPSY; T LYMPHOCYTE; TUMOR CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; RECEPTORS, CXCR3; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84857971952     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Burg G, Kempf W, Cozzio A, Dobbeling U, Feit J, Golling P, et al. Cutaneous malignant lymphomas: Update 2006. JDDG. 2006; 4: 914-933.
2. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997; 90: 354-371.
3. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105: 3768-3785.
4. Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/ Sézary syndrome (cutaneous T cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes. Am J Surg Pathol. 1994; 18: 645-667.
5. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol. 1988; 132: 265-277.
6. Garcia-Lopez MA, Sanchez-Madrid F, Rodriguez-Frade JM, Mellado M, Acevedo A, Garcia MI, et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest. 2001; 81: 409-418.
7. Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Molecular Immunology. 2005; 42: 799-809.
8. Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol. 2009; 129: 1115-1119.
9. Kunkel SL. Through the looking glass: The diverse in vivo activities of chemokines. J Clin Invest. 1999; 104: 1333-1334.
10. Yagi H, Seo N, Ohshima A, Itoh T, Itoh N, Horibe T, et al. Chemokine receptor expression in cutaneous T cell and NK/T cell lymphomas: Immunohistochemical staining and in vitro chemotactic assay. Am J Surg Pathol. 2006; 30: 1111-1119.
11. Notohamiprodjo M, Segerer S, Huss R, Hildebrandt B, Soler D, Djafarzadeh R, et al. CCR10 is expressed in cutaneous T cell lymphoma. Int J Cancer. 2005; 115: 641-647.
12. Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol. 2003; 121: 1045-1052.
13. Tensen CP, Flier J, Van Der Raaij-Helmer EM, Sampat-Sardjoepersad S, Van Der Schors RC, Leurs R, et al. Human IP-9: A keratinocyte-derived high afinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol. 1999; 112: 716-722.
14. Sarris AH, Daliani D, Ulmer R CM, Broxmeyer HE, Reiss M, Karasavvas N, et al. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T cell lymphomas. Clin Cancer Res. 1997; 3: 169-177.
15. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998; 187: 129-134.
16. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol. 1995; 57: 726-730.
17. Hamann D, Hilkens CM, Grogan JL, Lens SM, Kapsenberg ML, Yazdanbakhsh M, et al. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol. 1996; 156: 1387-1391.
18. Barberio E, Thomas L, Skowron F, Balme B, Dalle S. Transformed mycosis fungoides: Clinicopathological features and outcome. Br J Dermatol. 2007;157: 284-289.
19. Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol. 2000; 165: 5105-5111.
20. Greisser J, Doebbeling U, Roos M, Mueller B, Schmid M, Burg G, et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol. 2005; 14: 380-385.
21. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009; 33(12): 1860-1868.
22. Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L, et al. Expression pattern of T cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T cell non-Hodgkin lymphoma. Blood. 2000; 96: 685-690.
23. Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T cell lymphoma, unspecified. Clin Cancer Res. 2004; 10: 5494-5500.
24. Lu D, Duvic M, Medeiros LJ, Luthra R, Dorfman DM, Jones D. The T cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol. 2001; 115: 413-421.
25. Winter D, Moser J, Kriehuber E, Wiesner C, Knobler R, Trautinger F, et al. Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol. 2007; 179: 4272-4282.
26. Dorfman DM, Shahsafaei A. CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. Hum Pathol. 2002; 33: 330-334.
27. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2- type cytokines. FASEB J. 1995; 9: 81-86.
28. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol. 2003; 12: 49-61.
29. Richardson SK, Newton SB, Bach TL, Budgin JB, Benoit BM, Lin JH, et al. Bexarotene blunts malignant T cell chemotaxis in Sezary syndrome: Reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am J Hematol. 2007; 82(9): 792-797.
30. Shimauchi T, Sugita K, Nishio D, Isoda H, Abe S, Yamada Y, et al. Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-[gamma] and narrowband UVB in patients with mycosis fungoides. J Dermatol Sci. 2008; 50(3): 217-225.
31. Yano H, Ishida T, Inagaki A, Ishii T, Ding J, Kusumoto S, et al. Defucosylated anti-CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2007; 13: 6494-6500.
32. Hino R, Shimauchi T, Tokura Y. Treatment with IFN-[gamma] increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. Journal of Dermatological Science. 2005; 38: 189-195